A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment

• Published in: Contemporary clinical trials communications 2023-06, Vol.33, p.101116-101116, Article 101116
• Main Authors: Difede, JoAnn, McAleavey, Andrew A., Emrich, Mariel, Jick, Adina, Ovalles, Annell, Wyka, Katarzyna, Spielman, Lisa, Olden, Megan, Peskin, Melissa, Becket-Davenport, Colleen, Rubenstein, Amy, Brownstein, Michael J., Damiano, Eve, Itzkowitz, Debra, Lu, Shi-fang, Needell, Nancy J., Kocsis, James H., Gordon-Elliott, Janna S., Simon, Neal G.
• Format: Article
• Language: English
• Subjects: Clinical trial; First-in-class medication; PTSD; Trauma; Vasopressin 1a receptor antagonist
• ISSN: 2451-8654; 2451-8654
• DOI: 10.1016/j.conctc.2023.101116

Almost eight million Americans suffer from Posttraumatic Stress Disorder (PTSD). Current PTSD drug therapies rely on repurposed antidepressants and anxiolytics, which produce undesirable side effects and have recognized compliance issues. Vasopressin represents a promising and novel target for pharmacological intervention. Logistical issues implementing a clinical trial for a novel PTSD pharmaceutical are relatively uncharted territory as trials concerning a new agent have not been published in the past several decades. All published trials have repurposed FDA-approved psychoactive medications with known risk profiles. Our recruitment challenges are discussed in this context. An 18-week proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist (SRX246) for PTSD was conducted. All participants received SRX246 for 8 weeks, the placebo for 8 weeks, and the drug vs. placebo arms were compared. Participants were assessed every 2 weeks for PTSD symptoms as well as other medication effects. Results were expected to provide an initial demonstration of safety and tolerability in this clinical population and potentially clinical efficacy in SRX246-treated patients measured by Clinician Administered PTSD Scale (CAPS) score changes, clinical impression, and other indices compared to placebo. The primary hypothesis was that SRX246 would result in a clinically meaningful 10-point reduction in mean CAPS score compared to placebo. This study is the first to investigate an oral vasopressin 1a receptor antagonist for PTSD. As a wave of PTSD clinical trials with new pharmaceutical compounds are beginning now, lessons learned from our recruitment challenges may be invaluable to these endeavors.